FyMed Inc., a specialty pharmaceutical company focused on the development and commercialization of novel therapeutics announced that its application covering the Fy10 technology platform was allowed for issuance as a new patent by the USPTO. Read More...

Tags: patent, drug discovery, precision medicine, fy10, antineoplastic, anti-inflammatory